BioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant
December 08 2021 - 06:15AM
BioNTech to Hold Digital Press Conference to Provide an Update on
Omicron Variant
MAINZ, Germany, December 8, 2021 – BioNTech SE (Nasdaq:
BNTX, “BioNTech” or “the Company”) will hold a digital press
conference on Wednesday, December 8, 2021, to present the results
from initial laboratory studies which started about two weeks ago.
The studies aimed to investigate the effects of the Omicron variant
on COVID-19 vaccine-induced immune responses. The press conference
will solely be held in a virtual format and will be conducted in
English.
International digital press conference at 3.00 pm CET / 9.00
am ETPlease register here.
The conference can be streamed. Interested
journalists may dial in 10 to 15 minutes before the conference
starts. They will be able to submit questions via an online
tool.There will be no access for journalists on-site.
Participants may also digitally access the press
conference on https://biontech.de/ under "Events &
Presentations" in the Investor & Media section of the website.
A recording of the press conference as well as the presentation
will be available under the section “Past Events” on the same
day.
About BioNTechBiopharmaceutical New
Technologies is a next generation immunotherapy company pioneering
novel therapies for cancer and other serious diseases. The Company
exploits a wide array of computational discovery and therapeutic
drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
checkpoint immuno-modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the
Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer.
For more information, please visit
www.BioNTech.de
Media RelationsJasmina Alatovic+49
(0)6131 9084 1513Media@biontech.de
Investor RelationsSylke Maas, Ph.D.+49
(0)6131 9084 1074Investors@biontech.de
Biontech (LSE:0A3M)
Historical Stock Chart
From Feb 2024 to Mar 2024
Biontech (LSE:0A3M)
Historical Stock Chart
From Mar 2023 to Mar 2024